Skip to main content

Table 3 Presence of a clinical response at 6 months by selected factors

From: HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma

Characteristics Clinical response (%) No clinical response (%) p-value
Age    0.488
  < 65 years old 28 (63.6) 16 (36.4)  
  ≥ 65 years old 19 (55.9) 15 (44.1)  
Gender    < 0.001
 Female 46 (71.9) 18 (28.1)  
 Male 1 (7.1) 13 (92.9)  
Degree of Cell Differentiation    0.387
 G I / G II 40 (62.5) 24 (37.5)  
 G III / G IV 7 (50.0) 7 (50.0)  
Clinical Stage (UICC)    < 0.001
 I - II 31 (86.1) 5 (13.9)  
 III A - III B 16 (38.1) 26 (61.9)  
T stage    < 0.001
 T 1 (≤2 cm) 1 (16.7) 5 (83.3)  
 T 2 (> 2 and ≤5 cm) 4 (13.3) 26 (86.7)  
 T 3 (>  5 cm) 15 (50.0) 15 (50.0)  
 T 4 (tumour invading adjacent organ) 11 (91.7) 1 (8.3)  
N stage    0.035
 Negative 40 (66.7) 20 (33.3)  
 Positive 7 (38.9) 11 (61.1)  
HPV    < 0.001
 Positive 47 (79.7) 12 (20.3)  
 Negative 0 (0.0) 19 (100.0)  
HIV    0.063
 Positive 8 (42.1) 11 (57.9)  
 Negative 39 (66.1) 20 (33.9)  
P16    < 0.001
 Positive 45 (78.9) 12 (21.1)  
 Negative/borderline 2 (9.5) 19 (90.5)  
TP53    < 0.001
 Mutant 2 (9.5) 19 (90.5)  
 Wild type 45 (78.9) 12 (21.1)  
  1. Statistically significant p-values are shown in bold